Thread by @COREIMpodcast

1/ November 14th is #WorldDiabetesDay

Let’s look back at one of the most influential #RCTs for

how we given insulin in #T2DM?

the #RABBIT2 trial🐰🧵

#Insulin #MedTwitter

2/ The #RABBIT2 study looked at the (1) efficacy and (2) safety of basal-bolus vs. sliding-scale #insulin in non-critical inpatients🏥.

Basal-bolus regimens consisted of a combo of #Glargine (basal) and #Glulisine (mealtime).

The primary outcome was average glucose🍬.

3/ See below for a graphical depiction of how the study was performed👇:

4/ What did #RABBIT2 show?

Basal-bolus #insulin resulted in lower average glucose and more #T2DM patients reaching their glycemic target compared to a sliding-scale regimen🥳

All the while rates of #hypoglycemia remained similar between the 2⃣ groups

Any lingering thoughts⁉️

5/ How could future studies build on #RABBIT2🧐

Some suggested repeating study while continuing oral DM meds (OHA)

Others wanted to see an intention-to-treat (ITT) analysis😮

For deeper learning, click here:
tinyurl.com/2p87h4s2 (ITT)
tinyurl.com/2p8jmy69 (OHA)

6/ A BIG thank you to the incredible team who "hopped" at the chance to build this byte on #RABBIT2🐰:

Thread: @YichiZzzzz
Graphics: @elizzieh08
Review: @ShreyaTrivediMD, @cwgillihan, Dr. Vivien Fonseca, Dr. Chayan Chakraborti, Dr. Robert Wharton

#WorldDiabetesDay2022